Contribution of meta-analyses to the evaluation of treatments for advanced colorectal cancer

References

• Boissel JP, Blanchard J, Panak E et al Considerations for the meta-analysis of randomized clinical trials. Summary of a panel discussion. Cont. Clin. Trials 10, 254–281 (1989).
   PubMedGoogle Scholar
• Chalmers I, Haynes B. Reporting, updating and correcting systematic reviews of the effects of healthcare. BE Merl 1. 309,862–865 (1994).
   Google Scholar
• Advanced Colorectal Cancer Meta-analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J. Clin. arca 10, 896–903 (1992).
   PubMed Web of Science ®Google Scholar
• •• Individual patient data meta-analysis confirming the advantage of the modulation of fluorouracil by leucovorin in terms of tumor response in patients with advanced colorectal cancer.
   Google Scholar
• Advanced Colorectal Cancer Meta-analysis Project. Meta-analysis of randomized trials testing the biochemical modulation of 5-fluorouracil by methotrexate in metastatic colorectal cancer. j Clin. Oncol 12,960–969 (1994).
   Google Scholar
• •Individual patient data meta-analysis, confirming the small but significant survival advantage of fluorouracil modulation by methotrexate in patients with advanced colorectal cancer.
   Google Scholar
• Meta-Analysis Group In Cancer. Alpha-interferon does not increase the efficacy of 5-fluorouracil in advanced colorectal cancer. Br. Cancer84, 611–620 (2001).
   Google Scholar
• •Individual patient data meta-analysis that confirms the lack of efficiency of fluorouracil biomodulation when using interferon.
   Google Scholar
• Meta-Analysis Group In Cancer. Efficacy of iv. continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. j Clin. Oncol 16, 301–308 (1998).
   Google Scholar
• ••Individual patient data meta-analysisconfirming the tumor response and survival advantage of continuous infusion over bolus fluorouracil in patients with advanced colorectal cancer.
   Google Scholar
• Meta-Analysis Group In Cancer. Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. j Natl Cancer Inst. 88, 252–258 (1996). Individual patient data meta-analysis confirming the tumor response advantage of HAT chemotherapy over intravenous fluorouracil in patients with advanced colorectal cancer metastatic to the liver.
   Google Scholar
• WHO Handbook for reporting results of cancer treatment. WHO offsets publication No 48, World Health Organization, Geneva, Switzerland, (1979).
   Google Scholar
• Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 47,207–214 (1981).
   PubMed Web of Science ®Google Scholar
• Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. J. Natl Cancer Inst. 92,205–216 (2000).
   PubMed Web of Science ®Google Scholar
• Meta-Analysis Group In Cancer. Toxicity of 5-fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J. Clin. Oncol 16, 1–6 (1998).
   Google Scholar
• ••Individual patient data meta-analysisconfirming the tumor response and survival advantage of continuous infusion over bolus fluorouracil, with different tolerance profiles in patients with advanced colorectal cancer.
   Google Scholar
• Machover D, Goldschmidt E, Chollet P et al. Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid. J. Clin. Oncol 4, 685–696 (1986).
   Google Scholar
• Evans RM, Laskin JD, Hakala MT. Effect of excess folates and deoxyinosine on the activity and site of action of 5-fluorouracil. Cancer Res. 41,3288-3295 (1981).
   Google Scholar
• Berger SH, Hakala MT Relationship of dUMP and free FdUMP pools to inhibition of thymidilate synthetase by 5-fluorouracil. Mal Pharmacol 25,303–309 (1984).
   PubMed Web of Science ®Google Scholar
• Waxman S, Bruckner H. The enhancement of 5-fluorouracil antimetabolic activity by leucovorin, menadione and a-tocopherol. Eur. Cancer Clin. Oncol 18, 685–692 (1982).
   Google Scholar
• Bertino JR, Sawicki WL, Linguist CA et al Schedule-dependent antitumor effects of methotrexate and 5-fluorouracil. Cancer Res. 37,327–328 (1977).
   PubMed Web of Science ®Google Scholar
• Allegra CJ. Methotrexate and fluorouracil following tamoxifen and premarin in advanced breast cancer. Semin. Oncol 10\(Suppl. 2), 23–28 (1983).
   Google Scholar
• Curt GA, Allegra CJ, Fine RL et al. Antimetabolites. In: Cancer Chemotherapy Ann. a Chapter 1, Elsevier Publ. (1984).
   Google Scholar
• Elias L, Crissman HA. Interferon effects upon the adenocarcinoma 38 and HL-60 cell lines: antiproliferative responses and synergistic interactions with halogenated pyrimidine antimetabolites. Cancer Res. 48, 4868–4873 (1988).
   PubMed Web of Science ®Google Scholar
• Wadler S, Wersto R, Weinberg V et al Interaction of fluorouracil and interferon in human colon cancer cell lines: cytotoxic and cytokinetic effects. Cancer Res. 50, 2653–2665 (1990).
   Google Scholar
• Neefe JR, John W Mechanisms of interaction of interferon and 5-fluorouracil in solid tumors. Semin. Oncol 18 (Suppl. 7), 77–82 (1991).
   Google Scholar
• Myers CE, Diasio R, Eliot HM et al Pharmacokinetics of the fluoropyrimides: implications for their clinical use. Cancer 7i-eat. Rev 3,175–183 (1975).
   Google Scholar
• Fraile RJ, Baker LH, Buroker TR et al Pharmacokinetics of 5-fluorouracil administered orally, by rapid iv. and by slow infusion. Cancer Res 40, 2223–2228 (1980).
   Google Scholar
• Aschele C, Sobrero A, Faderan MA, Bertino JR. Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules. Cancer Res. 52,1855–1864 (1992).
   PubMed Web of Science ®Google Scholar
• Carlson R. Continuous iv. infusion chemotherapy. In: The Chemotherapy Source Book. Perry MC (Ed.), Williams & Wilkin, Baltimore, ML, USA, (1996).
   Google Scholar
• Chen GHG, Gross JR Intra-arterial infusion of anticancer drugs: theoretic aspects of drug delivery and review of responses. Cancer Beat. Rep. 64,31–40 (1980).
   Google Scholar
• Ensminger WD, Gyves RV. Regional chemotherapy of neoplastic diseases. Pharmacol Ther. 21,277–293 (1983).
   PubMed Web of Science ®Google Scholar
• Hoff PM, Ansari R, Batist G et al Comparison of oral capecitabine versus iv. fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized Phase III study. I Clin. Oncol 19,2282–2292 (2001).
   Google Scholar
• Van Cutsem E, Twelves C, Cassidy J et al. Oral capecitabine compared with iv. 5-fluorouracil plus leucovorin (Mayo Clinic regimen) in patients with metastatic colorectal cancer: results of a large Phase DI study. Clin. Oncol 19, 4097–4106 (2001).
   Google Scholar
• Buyse M, Thirion P, Carlson RVV et al Relation between tumor response to first-line chemotherapy and survival in advanced
   Google Scholar
• ••colorectal cancer: a meta-analysis. Lancet 356, 373–378 (2000). This individual patient data meta-analysis confirms the relationship between tumor response and survival in advanced colorectal cancer.
   Google Scholar
• Buyse M, Zeleniuch-Jacquotte A, Chalmers TC. Adjuvant therapy of colorectal cancer: why we still don't know. jAm. Med. Assoc. 259, 3571–3578 (1988).
   PubMed Web of Science ®Google Scholar
• Piedbois P, Bugat R, Ganem G et al. Intravenous 5-FLYLV + CPT11 combined with hepatic arterial infusion pirarubicin in nonresectable liver metastases from colorectal cancer. Proc. Am. Soc. Clin. Oncol 19, (2000) (Abstract 1056).
   Google Scholar
• Cochran WG. The combination of estimates from different experiments. Biometrics 10, 101–129 (1954).
   Web of Science ®Google Scholar
• Whitehead J, Whitehead A. A general parametric approach to the meta-analysis of randomized clinical trials. Statist. Med. 10, 1665–1677 (1991).
   PubMed Web of Science ®Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Cont. Clin. 7itals7, 177–188 (1986).
   Google Scholar
• Mantel N, Haenszel W Statistical aspects of the analysis of data from retrospective studies of diseases. J. Natl Cancer Inst. 22, 719–748 (1959).
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists' Collaborative Group. The effects of Tamoxifen and of cytotoxic therapy on mortality in early breast cancer: an overview of 61 randomized trials among 28 896 women. N. Engl J. Med. 190, 1681–1692 (1988).
   Google Scholar
• Liver Infusion Meta-Analysis Group. Portal vein infusion of cytotoxic drugs after colorectal cancer surgery: a meta-analysis of 10 randomized studies involving 4000 patients. J. Nall Cancer Inst. 89, 497–505 (1997).
   Google Scholar
• •This individual patient data meta-analyses evaluates the benefit of portal vein infusion chemotherapy after colorectal surgery
   Google Scholar
• Wachter KW Disturbed by meta-analysis? Science 241, 1407–1408 (1988).
   Google Scholar
• Buyse M, Piedbois P Meta-Analyses, use and misuse (Letter). J. Clin. Oncolll, 382 (1993).
   Google Scholar
• Pogue J, Yusuf S. Overcoming the limitations of current meta-analysis of randomised controlled trials. Lancet 351, 47–52 (1998).
   PubMedGoogle Scholar
• Collins R, Gray R, Godwin J, Peto R. Avoidance of large biases and large random errors in the assessment of moderate treatment effects: the need for systematic overviews. Statist. Med. 6, 245–250 (1987).
   PubMed Web of Science ®Google Scholar
• Durand-Zaleski I, Roche B, Buyse M et al. for the Meta-Analysis Group in Cancer. Pharmacoeconomic implications of hepatic arterial infusion versus iv. chemotherapy for the treatment of liver metastases of colorectal cancer origin. J. Natl Cancer Inst. 89, 790–795 (1997).
   Google Scholar
• Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women. Lancet 339, 1–27 and 72–85 (1992).
   Google Scholar
• Early Breast Cancer Trialists' Collaborative Group. Effects of radiotherapy and surgery in early breast cancer. An overview of the randomized trials. N Engl J. Med. 333, 1444–1455 (1995).
   Google Scholar
• Buyse M. Potential and pitfalls of randomized clinical trials in cancer research. Cancer Surv. 8, 91–105 (1989).
   PubMedGoogle Scholar
• Buyse M, Piedbois P, Carlson RW. Meta-analyses based on published data are unreliable (Letter). J. Clin. Oncol 17, 1646–1647 (1999).
   Google Scholar
• Piedbois P, Buyse M. Meta-analyses need time, collaboration and funding (Letter). Clin. °Tirol 12, 878–879 (1994).
   PubMedGoogle Scholar
• Buyse M, Piedbois P, Piedbois Y, Carlson R. Meta-analysis: methods, strengths and weaknesses. Oncology14, 437–443 (2000).
   PubMedGoogle Scholar
• Moher D, Olkin I. Meta-analysis of randomised controlled trials: a concern for standards. jAm. Med. Assoc. 274, 1962–1964 (1995).
   PubMedGoogle Scholar
• Clarke MJ, Stewart LA. Obtaining data from randomised controlled trials: how much do we need for reliable and informative meta-analyses? BE Med. J. 309, 1007–1010 (1994).
   Google Scholar
• Piantadosi S. Clinical Trials. A Methodologic Perspective. John Wiley, New York, NY, USA, (1997).
   Google Scholar